

ProbeHunter Team announces program with Cephasonics to develop probe adapters for the Cephasonics ultrasound platform




Ultrasound probe adapters, all brands, will now be available to the research platform Cephasonics. BBS Medical AB from Sweden is to develop and market specialized ultrasound probe/transducer adapters that allow users of Cephasonics systems to connect a variety of different probes from other companies to the Cephasonics system. As part of the relationship BBS Medical in Sweden/ProbeHunter Team will develop and market the adapters both directly as well as through Cephasonics.

Björn Segall, BBS Medical AB/ProbeHunter CEO, comments: "We are proud to announce that one of the leading programmable platforms within ultrasound research, Cephasonics, enter in to a co-operation with us at BBS Medical AB from Sweden as a developer of adapters to their system. This collaboration enables all universities and OEM's to quickly get support with adapters for their ultrasound research and development platforms. Five years ago we released ProbeHunter, the real time test system, to verify the performance of ultrasound probes all brands. To the ProbeHunter system there are today approximately 50 different adapters to test all leading brands; GE, Philips, Siemens, Samsung, Toshiba/Canon, etc. The new adapters to Cephasonics will support probes initially from Ultrasonix and overtime a growing number of probes from other major ultrasound companies to be directly connected to the Cephasonics system.

According to Randy Whiting, chief operating officer COO of Cephasonics, "this product will provide our users and developers a much greater array of ultrasound probes that can be used in research and development with the Cephasonics ultrasound engine. We're very excited to work with BBS Medical and the ProbeHunter team to expand the ability of our platform to work with popular ultrasound probes."

www.bbsmedical.se



Safety syringe demand to 2023

Almost a decade since sharps legislation was passed in the USA and Europe, compliance still has a way to go to reach mandatory legal requirements in hospitals and even more so in non-hospital locations such as the home. The latter is becoming increasingly important in the drive to increase self-administration and independence in management of chronic diseases. To understand future demand for safety syringes, Owen Mumford, a global industry leader in medical device design and manufacturing, commissioned third-party research into trends and drivers surrounding safety-device take up.

Economic pressures on healthcare efficiency are in fact encouraging greater patient self-administration/homecare. Pre-filled syringes are facilitating this move as they help patients manage treatment and dosage. Another important driver towards regular self-administration is fuelled by new biological therapies and competitive biosimilar markets that are mostly administered via subcutaneous injection. Finally, longer life expectancy, combined with a rise in obesity, diabetes, cancers and heart disease are also driving the push towards self-administration.

The survey estimates that:

- The global safety syringe market is experiencing a growth rate of 8.96% per year;
- The global pre-filled syringe market is expected to rise to \$1.137 billion by 2023;
- Safety-engineered pre-filled syringes dominate the total pre-filled market, with approximately 76% share of the total pre-filled demand in 2023;

- This dominance could suggest that pharmaceutical and biotechnology firms consider safety features to be highly attractive to users and are thus favouring their production as a key element for their combination products.

George Ions at Owen Mumford comments: "This latest analysis provides a clear view of the factors that are at play in the safety device market, roughly ten years from the introduction of legislation making measures to prevent needlestick injury mandatory. Although compliance has improved massively in hospital environments there is still some way to go. In addition to this the increasing push to drive patients to manage their conditions at home means that homecare settings are also increasingly coming under scrutiny.

"As a result, market projections are buoyant with safety device demand expected to grow across the world. Pre-filled syringes designed to help patients manage prescription and dosage accuracy are expected to grow with particular strength. Safety-engineered devices comfortably dominate the pre-filled market, indicating that pharmaceutical firms regard safety features as a key differentiator."

A full copy of the whitepaper – "Safety First!" is available on:

https://www.ompharmaservices.com/wp-content/uploads/2019/09/OMPS_WhitePaper_Safety_First.pdf

More than 9 in 10 surgeons encounter a needlestick injury

95% of surgeons have either been personally affected by a needlestick injury or have seen a colleague experience one, a new global survey has found, increasing their risk of infection. The survey – the first of its kind undertaken – was conducted by SERMO for Mölnlycke, a wound care and surgical products company.

